u/freya_baptista

area% is not mass%, and here is exactly why it matters

stalled at 2.4mg, went up, and regretted it, the stall would have broken anyway

retatrutide is not approved anywhere for human use, posts must not read as instructions

PDF metadata is checkable in fifteen seconds

the method line is doing real work, not just window dressing

triple agonism is phase 2, do not generalise

the detector wavelength matters more than people think

Adding to this: integration is doing more work than the comment implies.

Disagree but this is the good kind of wrong — it is specific enough to be checked.

Ran the same vial on two columns, different purity, both right, different separation.

Yes, exactly this, and it is the bit that took me 49 weeks to accept.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

not approved anywhere, keep posts descriptive, not instructional

REDEFINE phase 23 readouts are interesting but 23 person cagrilintide is different from 23 trial cagrilintide.

The research community is small on cagrilintide. Forum lore changes faster than data.

Did they post the raw trace or just the summary?

I am going to push back on this slightly.

no "is this good?" without saying what the compound and claimed purity are

ALT is where the fatty-liver story shows up first

Disagree. What you are describing is consistent with gradient, not with what you concluded.

Respectfully this is a sample of one presented as a finding.